Please enable Javascript
Conferences
Partners
Expert Interviews
Subscribe
Heme Today
Anemia
Deep Vein Thrombosis
Essential Thrombocythemia
Hemophilia
Immune Thrombocytopenic Purpura
Myelodysplastic Syndromes
Myelofibrosis
Myeloproliferative Neoplasms
PNH
Polycythemia Vera
Pulmonary Embolism
Sickle Cell Disease
Thrombocytopenia
Thrombophilia
Thrombosis
Thrombotic Thrombocytopenic Purpura
Venous Thromboembolism
von Willebrand Disease
Nephrology Times
Acute Kidney Injury
ADPKD
Anemia and Kidney Disease
Chronic Kidney Disease
COVID-19 and Kidney Disease
Diabetes and Hypertension
End-Stage Renal Disease
Gout
Hyperkalemia
IgAN
Kidney Transplantation
Metabolic Acidosis
Breast Cancers Today
HER2 Breast Cancer
HR Breast Cancer
Triple-Negative Breast Cancer
Genetics & Breast Cancer
Cardiology
Atherosclerotic Disease
Atrial Fibrillation
Heart Failure
Hypertension
Interventional Cardiology
Lipid Management
Practice Tips With Dr. Lichaa
Preventive Cardiology
Stroke
Oncology
Breast Cancer
Gynecologic Cancer
Head and Neck Cancer
Skin Cancer
Sleep
Urology
More
Diabetes
Ophthalmology
— Demodex Blepharitis
Neurology
Rheumatology
Gastroenterology
Pulmonology
Infectious Diseases
— HIV
Health and Wellness
Lupus
Future of Medicine
Orthopedics
Pharmacology
Career News
Andrew Moreno
Editor
Articles by Andrew Moreno
A New, Viable Approach in Hemophilia: Inhibition of Activated Protein C
Andrew Moreno
Hemophilia
|
May 20, 2025
A preclinical mouse study showed hemostasis restoration, as well as use for active bleeding and internal bleeding prevention.
Read More
Phase 2 Data Support a Safer Immunotherapy Option for PNH
Andrew Moreno
PNH
|
May 19, 2025
A novel complement-targeting agent shows impressive efficacy and safety without immunosuppression of the classical pathway.
Read More
Is Plasma Mannose-Binding Lectin a Clue to Higher VTE Risk?
Andrew Moreno
VTE
|
May 16, 2025
Investigation of a HUNT Study cohort found elevated plasma MBL levels to be associated with increased risk for future VTE.
Read More
Study Data Bolster Quercetin Treatment of Fanconi Anemia in Young Persons
Andrew Moreno
Anemia
|
May 16, 2025
Reactive oxygen species levels decreased and patients with evident bone marrow failure showed hematological response.
Read More
Extending Anticoagulation is Reasonable in Children with VTE, Data Suggest
Andrew Moreno
VTE
|
May 19, 2025
A cohort study of extended-phase anticoagulation following acute management was performed in the phase III EINSTEIN Jr trial.
Read More
Oral Histone Deacetylase Inhibitor Receives FDA Fast Track Designation for PV
Andrew Moreno
Polycythemia Vera
|
May 12, 2025
The agent targets abnormal gene expression in order to control the excessive cell proliferation that occurs in PV.
Read More
Study Links p53 Dysfunction to MDS Risk and Response
Andrew Moreno
MDS
|
May 12, 2025
A study has explored the clinical impact of both mutation-based and non-mutation-based p53 dysfunction in MDS.
Read More
Promising Data Presented on Novel Radiotherapy for AML, MDS, Myeloid Malignancies
Andrew Moreno
MDS
|
May 9, 2025
Preclinical models show significant efficacy in combos against AML cell lines with FLT3, KMT2A, NPM1, and TP53 mutations.
Read More
AI-Driven Tools Enhance CAR T-Cell Therapy Research, Patent Filing
Andrew Moreno
Hematology
|
May 7, 2025
Investigators used two AI-driven tools to analyze multiple myeloma therapies' clinical literature and patent information.
Read More
Belantamab Mafodotin Combos for Relapsed or Refractory Multiple Myeloma Approved for the First Time
Andrew Moreno
Hematology
|
May 5, 2025
The two specific combinations recently approved by the MHRA in the UK also have a BLA currently under review at the FDA.
Read More
Trial of New Agent for CRS in CAR T-Cell Recipients Advances from Its Initial Dosing Cohort
Andrew Moreno
Hematology
|
May 5, 2025
The agent produced favorable safety results, had no dose-limiting toxicities, and did not interfere with CAR T-cell therapy.
Read More
Real-World Database Study Affirms Long-Term Benefit of Hydroxyurea for Anemia in Pediatric SCD
Paul George, MD, PhD
Sickle Cell Disease
|
May 8, 2025
The study led by Paul George, MD, PhD, also highlights the importance of patient regimen adherence to secure these benefits.
View More
FDA Approves Fitusiran With or Without Inhibitors for Bleeding Prophylaxis in Hemophilia A, B
Andrew Moreno
Hemophilia
|
April 30, 2025
Approval was based on data from phase 3 studies in the ongoing ATLAS clinical development program.
Read More
Study of Women with SCD Suggests C-Reactive Protein Level Link to Menstrual Cycle
Andrew Moreno
Sickle Cell Disease
|
April 29, 2025
The findings coincide with patient reports of experiencing increased vaso-occlusive episodes during menses.
Read More
How Is Machine Learning Augmenting Decision Making in Myelofibrosis Care?
Adrián Mosquera Orgueira, MD, PhD
Myelofibrosis
|
April 25, 2025
Adrián Mosquera Orgueira, MD, PhD, spoke of his team's study into machine learning tools for improving risk stratification.
View More
Antithrombotic Care in Hemophilia: A Summary of Multi-Organizational Clinical Practice Guidance
Andrew Moreno
Hemophilia
|
April 23, 2025
The Clinical Practice Guidance document issued by the EHA, ISTH, EAHAD, and ESO addresses both hemophilia A and B.
Read More
Study: Differences in Malignant Hematologic Neoplasm Cytokine Storm Etiology Have Clinically Meaningful Effects
Andrew Moreno
Hematology
|
April 21, 2025
Malignant neoplasm-associated hemophagocytic lymphohistiocytosis, COVID-19, and CAR T-cell therapy can each initiate CS.
Read More
Novel Cell Therapy Product for Bone Marrow Failure Syndromes Receives FDA Aplastic Anemia Orphan Drug Designation
Andrew Moreno
Anemia
|
April 15, 2025
In a phase 1 trial the product performed favorably in aplastic anemia, myelofibrosis, and hypoplastic myelodysplasia.
Read More
Reduced-Dose Apixaban Anticoagulation Noninferior to Full Dose in Prevention of Cancer-Associated VTE
Andrew Moreno
VTE
|
April 15, 2025
The reduced-dose oral regimen also had lower incidence of clinically relevant bleeding complications and mortality rate.
Read More
Biotechnology Company Grants Commercial License for Cell Manufacturing Platform Use to Advance SCD Therapy
Andrew Moreno
Sickle Cell Disease
|
April 8, 2025
The platform features incubation technology able to replicate cell microenvironments associated with SCD sickling.
Read More
Load More